Umoja hopes to transform the future of cancer treatment by combining a deep understanding of immune physiology and genetic engineering with the most advanced, integrated cellular immunotherapy platform for cancer treatment currently under development.
Our treatment approach retools a patient’s immune system in vivo to direct potent anti-cancer immune cells to a patient’s tumor, augmenting the body’s natural mechanisms for fighting cancer.
Personalized therapy without complex and costly manufacturing
No lengthy treatment timelines
An “off the shelf” treatment that is accessible to patients everywhere
Umoja is committed to developing therapies that enable all patients to live better, fuller lives without the burden and side effects associated with many current cancer treatments.
We have assembled a diverse, highly skilled, and passionate team that combines specific expertise and experience with in vivo gene transfer, drug development, and oncology.
Latest News
Umoja Biopharma Expands Management Team with Key Hires in Research and Business Development
Seattle, Wash., July 27, 2021 – Umoja Biopharma, an oncology company leveraging its proprietary integrated technologies to reprogram immune cells in vivo to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, today announced the appointments of three new hires in the company’s research and business development functions, including Bruce Kerwin, Ph.D. as Senior Vice President of Process and Product Development, Ryan Larson, Ph.D. as Vice President and Head of Translational Science, and Mike Fitzpatrick as Vice President of Business Development and Operations.
Umoja Biopharma Closes an Oversubscribed $210 Million Series B Financing to Expand Integrated Immunotherapy Platforms and Advance Programs to the Clinic
Seattle, Wash., June 15, 2021 – Umoja Biopharma, an oncology company leveraging its proprietary integrated technologies to reprogram immune cells in vivo to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, today announced the completion of an oversubscribed $210 million Series B financing.
Umoja Biopharma Announces Appointment of David Fontana, Ph.D., as Chief Business and Strategy Officer
Seattle, WA, June 8, 2021– Umoja Biopharma, a leading oncology company leveraging its proprietary, integrated technologies to reprogram immune cells directly in the human body to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, today announced the appointment of David Fontana, Ph.D., as Chief Business and Strategy Officer.